Stage T1 bladder cancer: diagnostic criteria and pitfalls

Pathology - Tập 53 - Trang 67-85 - 2021
Antonio Lopez-Beltran1, Liang Cheng2
1Department of Morphological Sciences, Cordoba University Medical School, Cordoba, Spain
2Department of Pathology, Indiana University School of Medicine, Indianapolis, USA

Tài liệu tham khảo

Lopez-Beltran, 2003, Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance, Pathology, 35, 484, 10.1080/00313020310001619127

Malmstrom, 1987, Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up, Scand J Urol Nephrol, 21, 185, 10.3109/00365598709180320

Cheng, 2009, Staging and reporting of urothelial carcinoma of the urinary bladder, Mod Pathol, 22, 70, 10.1038/modpathol.2009.1

Cheng, 2000, Predicting the survival of bladder carcinoma patients treated with radical cystectomy, Cancer, 88, 2326, 10.1002/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO;2-T

Eble, 2004, WHO Classification of Tumours. Pathology and Genetics:

Moch, 2016

Amin, 2018

Jordan, 2019, T1 bladder cancer: current considerations for diagnosis and management, Nat Rev Urol, 16, 23, 10.1038/s41585-018-0105-y

Magers, 2019, Staging of bladder cancer, Histopathology, 74, 112, 10.1111/his.13734

Esrig, 1997, Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder, Semin Urol Oncol, 15, 154

Martin-Doyle, 2015, Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients, J Clin Oncol, 33, 643, 10.1200/JCO.2014.57.6967

Lopez-Beltran, 2001, A practical approach to bladder sampling and diagnostic reporting of pathological findings, Pathologica, 93, 688

Jimenez, 2000, pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications, Adv Anat Pathol, 7, 13, 10.1097/00125480-200007010-00004

Cheng, 2012

Bostwick, 1999, Diagnosis and grading of bladder cancer and associated lesions, Urol Clin North Am, 26, 493, 10.1016/S0094-0143(05)70197-X

Raspollini, 2020, pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging, Virchows Arch, 477, 3, 10.1007/s00428-020-02808-6

Amin, 2015, Update for the practicing pathologist: the International Consultation on Urologic Disease-European Association of Urology consultation on bladder cancer, Mod Pathol, 28, 612, 10.1038/modpathol.2014.158

Varma, 2020, Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR), Mod Pathol, 33, 700, 10.1038/s41379-019-0403-9

Cheng, 2000, Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens, Am J Clin Pathol, 113, 275, 10.1309/94B6-8VFB-MN9J-1NF5

Cheng, 2000, Predicting extravesical extension of bladder carcinoma: a novel method based on micrometer measurement of the depth of invasion in transurethral resection specimens, Urology, 55, 668, 10.1016/S0090-4295(99)00595-6

Dixon, 1983, Histology and fine structure of the muscularis mucosae of the human urinary bladder, J Anat, 136, 265

Ro, 1987, Muscularis mucosa of urinary bladder. Importance for staging and treatment, Am J Surg Pathol, 11, 668, 10.1097/00000478-198709000-00002

Engel, 1992, The muscularis mucosae of the human urinary bladder. Implications for tumor staging on biopsies, Scand J Urol Nephrol, 26, 249, 10.3109/00365599209180877

Lopez-Beltran, 2020, Nonneoplastic disorders of the urinary bladder

Akgul, 2020, The applicability and utility of immunohistochemical biomarkers in bladder pathology, Hum Pathol, 98, 32, 10.1016/j.humpath.2020.01.004

Hodges, 2010, Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia, Appl Immunohistochem Mol Morphol, 18, 401, 10.1097/PAI.0b013e3181e04816

Wilkerson, 2014, The application of immunohistochemical biomarkers in urologic surgical pathology, Arch Pathol Lab Med, 138, 1643, 10.5858/arpa.2014-0078-RA

Cheng, 2020

Amin, 2014, Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference, Am J Surg Pathol, 38, 1017, 10.1097/PAS.0000000000000254

Paner, 2010, Diagnostic use of antibody to smoothelin in the recognition of muscularis propria in transurethral resection of urinary bladder tumor (TURBT) specimens, Am J Surg Pathol, 34, 792, 10.1097/PAS.0b013e3181da7650

Council, 2009, Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma, Mod Pathol, 22, 639, 10.1038/modpathol.2009.9

Miyamoto, 2010, Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma, Am J Surg Pathol, 34, 418, 10.1097/PAS.0b013e3181ce5066

Cheng, 2012, Histologic grading of urothelial carcinoma: a reappraisal, Hum Pathol, 43, 2097, 10.1016/j.humpath.2012.01.008

Comperat, 2019, Grading of urothelial carcinoma and the new “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”, Eur Urol Focus, 5, 457, 10.1016/j.euf.2018.01.003

MacLennan, 2007, Histologic grading of noninvasive papillary urothelial neoplasms, Eur Urol, 51, 889, 10.1016/j.eururo.2006.10.037

Toll, 2012, Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases, Am J Surg Pathol, 36, 1081, 10.1097/PAS.0b013e318253d6e0

Jones, 2020, Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP), Histopathology, 77, 525, 10.1111/his.14192

Lopez-Beltran, 2002, Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation, Virchows Arch, 440, 3, 10.1007/s00428-001-0577-6

Lopez-Beltran, 2010, Invasive micropapillary urothelial carcinoma of the bladder, Hum Pathol, 41, 1159, 10.1016/j.humpath.2009.11.018

Yang, 2020, Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma, Urol Oncol, 38, 449, 10.1016/j.urolonc.2019.10.013

Lopez-Beltran, 2006, Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications, Hum Pathol, 37, 1371, 10.1016/j.humpath.2006.05.009

Cheng, 2011, Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation, Am J Surg Pathol, 35, e34, 10.1097/PAS.0b013e3182159dec

Lopez-Beltran, 1999, Bladder treatment. Immunotherapy and chemotherapy, Urol Clin North Am, 26, 535, 10.1016/S0094-0143(05)70199-3

Lopez-Beltran, 2002, Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer, J Clin Pathol, 55, 641, 10.1136/jcp.55.9.641

Lopez-Beltran, 2017, Iatrogenic changes in the urinary tract, Histopathology, 70, 10, 10.1111/his.13090

Lott, 2007, Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential, Hum Pathol, 38, 807, 10.1016/j.humpath.2007.03.017

Lott, 2007, Soft tissue tumors of the urinary bladder Part II: malignant neoplasms, Hum Pathol, 38, 963, 10.1016/j.humpath.2007.03.016

Paner, 2007, Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma, Am J Surg Pathol, 31, 1420, 10.1097/PAS.0b013e3180588283

Lindh, 2011, Detection of smoothelin expression in the urinary bladder is strongly dependent on pretreatment conditions: a critical analysis with possible consequences for cancer staging, Virchows Arch, 458, 665, 10.1007/s00428-011-1076-z

Farrow, 1982, Observation on microinvasive transitional cell carcinoma of the urinary bladder, Clin Oncol, 1, 609

Chang, 2012, Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection, Am J Surg Pathol, 36, 454, 10.1097/PAS.0b013e31823dafd3

van der Aa, 2005, A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation, Hum Pathol, 36, 981, 10.1016/j.humpath.2005.06.017

Bertz, 2011, Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series, Histopathology, 59, 722, 10.1111/j.1365-2559.2011.03989.x

van Rhijn, 2012, A new and highly prognostic system to discern T1 bladder cancer substage, Eur Urol, 61, 378, 10.1016/j.eururo.2011.10.026

Williamson, 2010, Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art, Crit Rev Oncol Hematol, 76, 112, 10.1016/j.critrevonc.2010.01.005

Cheng, 1999, Predicting cancer progression in patients with stage T1 bladder carcinoma, J Clin Oncol, 17, 3182, 10.1200/JCO.1999.17.10.3182

Cheng, 1999, Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal, Cancer, 86, 1035, 10.1002/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D

Lopez-Beltran, 2008, Bladder cancer: clinical and pathological profile, Scand J Urol Nephrol Suppl, 95, 10.1080/03008880802325226

Lawless, 2017, Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression, Histopathology, 71, 406, 10.1111/his.13247

Lopez-Beltran, 2019, Variants and new entities of bladder cancer, Histopathology, 74, 77, 10.1111/his.13752

Lobo, 2020, What is the significance of variant histology in urothelial carcinoma?, Eur Urol Focus, 6, 653, 10.1016/j.euf.2019.09.003

Lopez-Beltran, 2009, Plasmacytoid urothelial carcinoma of the bladder, Hum Pathol, 40, 1023, 10.1016/j.humpath.2009.01.001

Kaimakliotis, 2014, Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?, Urol Oncol, 32, 833, 10.1016/j.urolonc.2014.03.008

Kaimakliotis, 2014, Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes, Urology, 83, 1112, 10.1016/j.urology.2013.12.035

Perrino, 2019, Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients, Hum Pathol, 90, 27, 10.1016/j.humpath.2019.04.012

Abufaraj, 2019, Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes, Eur Urol, 75, 649, 10.1016/j.eururo.2018.11.052

Hodges, 2011, Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management, BJU Int, 107, 532, 10.1111/j.1464-410X.2010.09853.x

Comperat, 2013, An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps, Histopathology, 63, 756, 10.1111/his.12214

Lopez-Beltran, 2011, Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP), Histopathology, 58, 579, 10.1111/j.1365-2559.2011.03784.x

Hodges, 2010, Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features, Hum Pathol, 41, 155, 10.1016/j.humpath.2009.07.002

Lopez-Beltran, 2004, Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group, Virchows Arch, 445, 103, 10.1007/s00428-004-1039-8

Lopez Beltran, 2014, Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour, Histopathology, 64, 872, 10.1111/his.12345

Beltran, 2014, Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder, Virchows Arch, 465, 199, 10.1007/s00428-014-1601-y

Brimo, 2015, Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant, Hum Pathol, 46, 1506, 10.1016/j.humpath.2015.06.010

Warrick, 2020, Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. II. Molecular pathology of bladder cancer: progress and challenges, Am J Surg Pathol, 44, e30, 10.1097/PAS.0000000000001453

Cheng, 2016, Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change, Histopathology, 69, 107, 10.1111/his.12920

Levy, 2020, The expanding molecular and mutational landscape of nested variant of urothelial carcinoma, Histopathology, 76, 638, 10.1111/his.14038

Akgul, 2019, Distinct mutational landscape of inverted urothelial papilloma, J Pathol, 249, 3, 10.1002/path.5307

Cheng, 2017, TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential, Eur Urol, 71, 497, 10.1016/j.eururo.2016.12.008

Priemer, 2018, Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common clonality between small-cell carcinoma of the urinary bladder and urothelial carcinoma, Eur Urol Focus, 4, 880, 10.1016/j.euf.2017.03.007

Wang, 2017, TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract, Future Oncol, 13, 705, 10.2217/fon-2016-0414

Comperat, 2018, A practical guide to bladder cancer pathology, Nat Rev Urol, 15, 143, 10.1038/nrurol.2018.2

Drew, 1996, The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology, Mod Pathol, 9, 989

Oliva, 2013, Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases, Hum Pathol, 44, 860, 10.1016/j.humpath.2012.08.011

McKenney, 2001, Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion, Am J Surg Pathol, 25, 356, 10.1097/00000478-200103000-00010

Lopez-Beltran, 2011, Flat urothelial carcinoma in situ of the bladder with glandular differentiation, Hum Pathol, 42, 1653, 10.1016/j.humpath.2010.12.024

Han, 2019, Patterns of urachal remnant involvement by urothelial carcinoma: intraluminal noninvasive spread can mimic a deep-seated bladder invasion, Am J Surg Pathol, 43, 475, 10.1097/PAS.0000000000001192

1993, Lamina propria microinvasion of bladder tumors, incidence on stage allocation (pTa vs pT1): recommended approach, World J Urol, 11, 161

Abel, 1988, Should pT1 transitional cell cancers of the bladder still be classified as superficial?, Br J Urol, 62, 235, 10.1111/j.1464-410X.1988.tb04325.x

Bol, 2003, Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder, J Urol, 169, 1291

Van Der Meijden, 2000, The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials, J Urol, 164, 1533

Tosoni, 2000, Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer, BJU Int, 85, 48, 10.1046/j.1464-410x.2000.00356.x

Bayraktar, 2002, Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy, Int J Urol Nephrol, 33, 627, 10.1023/A:1020553812554

Mhawech, 2002, Value of immunohistochemistry in staging T1 urothelial bladder carcinoma, Eur Urol, 42, 459, 10.1016/S0302-2838(02)00368-8

Naselli, 2018, Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis, Eur Urol Focus, 4, 558, 10.1016/j.euf.2016.12.011

Dalbagni, 2002, Impact of a second transurethral resection on the staging of T1 bladder cancer, Urology, 60, 822, 10.1016/S0090-4295(02)01920-9

Pagano, 1987, Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma, Eur Urol, 13, 145, 10.1159/000472760

Cumberbatch, 2018, Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review, Eur Urol, 73, 925, 10.1016/j.eururo.2018.02.014

Mostafid, 2020, Best practices to optimise quality and outcomes of transurethral resection of bladder tumours, Eur Urol Oncol, 10.1016/j.euo.2020.06.010

Miladi, 2003, The value of a second transurethral resection in evaluating patients with bladder tumors, Eur Urol, 43, 241, 10.1016/S0302-2838(03)00040-X

Sozen, 2002, Microstaging of pT1 transitional cell carcinoma of the bladder: does it really differentiate two populations with different prognoses?, Urol Int, 69, 200, 10.1159/000063941

Pan, 2013, Does muscularis mucosae invasion in extensively lamina propria-invasive high-grade papillary urothelial carcinoma provide additional prognostic information?, Am J Surg Pathol, 37, 459, 10.1097/PAS.0b013e3182796e72

Keep, 1989, Invasive carcinomas of the urinary bladder. Evaluation of tunica muscularis mucosae involvement, Am J Clin Pathol, 91, 575, 10.1093/ajcp/91.5.575

Platz, 1996, Is microstaging of early invasive cancer of the urinary bladder possible or useful?, Mod Pathol, 9, 1035

Angulo, 1995, Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer, Urology, 45, 47, 10.1016/S0090-4295(95)96490-8

Roupret, 2013, Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review, J Urol, 189, 2069

Lee, 2012, Prognostic significance of substaging according to the depth of lamina propria invasion in primary T1 transitional cell carcinoma of the bladder, Korean J Urol, 53, 317, 10.4111/kju.2012.53.5.317

Hasui, 1994, Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer, Urology, 43, 782, 10.1016/0090-4295(94)90134-1

Younes, 1990, The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder, Cancer, 66, 543, 10.1002/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R

Orsola, 2005, Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients, Eur Urol, 48, 231, 10.1016/j.eururo.2005.04.013

Holmang, 1997, The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study, J Urol, 157, 800

Hermann, 1998, The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer, J Urol, 159, 91

Brimo, 2013, Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion, Hum Pathol, 44, 95, 10.1016/j.humpath.2012.04.020

Hu, 2014, Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence, Ann Diagn Pathol, 18, 49, 10.1016/j.anndiagpath.2013.11.002

Patriarca, 2016, Usefulness of pT1 substaging in papillary urothelial bladder carcinoma, Diagn Pathol, 11, 6, 10.1186/s13000-016-0466-6

Colombo, 2018, Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer, Eur Urol Focus, 4, 87, 10.1016/j.euf.2016.06.004

Gontero, 2015, Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients, Eur Urol, 67, 74, 10.1016/j.eururo.2014.06.040

Leivo, 2018, Analysis of T1 bladder cancer on biopsy and transurethral resection specimens: comparison and ranking of T1 quantification approaches to predict progression to muscularis propria invasion, Am J Surg Pathol, 42, e1, 10.1097/PAS.0000000000000964

Cheng, 1999, Survival of patients with carcinoma in situ of the urinary bladder, Cancer, 85, 2469, 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U

Casey, 2015, Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review, Eur Urol, 67, 876, 10.1016/j.eururo.2014.10.040

Kim, 2014, Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis, Urol Oncol, 32, 1191, 10.1016/j.urolonc.2014.05.008

Lotan, 2005, Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy, J Clin Oncol, 23, 6533, 10.1200/JCO.2005.05.516

von Rundstedt, 2015, Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial, BJU Int, 116, 44, 10.1111/bju.12997

Fukumoto, 2016, Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers, Cancer Sci, 107, 1338, 10.1111/cas.12990

Rolim, 2020, Clinicopathologic analysis of upper urinary tract carcinoma with variant histology, Virchows Arch, 477, 111, 10.1007/s00428-020-02745-4

Burger, 2019, Does variant histology change management of non-muscle-invasive bladder cancer?, Eur Urol Oncol, S2588–9311, 30093

Li, 2019, The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy, Eur Urol Focus, 5, 104, 10.1016/j.euf.2017.06.013

Veskimäe, 2019, Eur Urol Oncol, 2, 625, 10.1016/j.euo.2019.09.003

Witjes, 2020, EAU-ESMO Consensus Statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort(†): under the auspices of the EAU-ESMO Guidelines Committees, Eur Urol, 77, 223, 10.1016/j.eururo.2019.09.035

Babjuk, 2019, European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update, Eur Urol, 76, 639, 10.1016/j.eururo.2019.08.016

Hedegaard, 2016, Comprehensive transcriptional analysis of early-stage urothelial carcinoma, Cancer Cell, 30, 27, 10.1016/j.ccell.2016.05.004

Rebola, 2019, Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype, Virchows Arch, 475, 445, 10.1007/s00428-019-02593-x

Dyrskjot, 2005, A molecular signature in superficial bladder carcinoma predicts clinical outcome, Clin Cancer Res, 11, 4029, 10.1158/1078-0432.CCR-04-2095

Robertson, 2020, Identification of differential tumor subtypes of T1 bladder cancer, Eur Urol, 78, 533, 10.1016/j.eururo.2020.06.048

Pietzak, 2017, Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets, Eur Urol, 72, 952, 10.1016/j.eururo.2017.05.032

Schnitzler, 2020, Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy, Cell Oncol, 43, 807, 10.1007/s13402-020-00524-6

Eckstein, 2019, PD-L1 assessment in urothelial carcinoma: a practical approach, Ann Transl Med, 7, 690, 10.21037/atm.2019.10.24

Cimadamore, 2020, Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view, Expert Opin Biol Ther, 20, 539, 10.1080/14712598.2020.1733965

Mann, 2017, Targeting the programmed cell death-1 pathway in genitourinary tumors: current progress and future perspectives, Curr Drug Metab, 18, 700, 10.2174/1389200218666170518162500

Gevaert, 2019, Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go, Future Oncol, 15, 2199, 10.2217/fon-2019-0217

Flaig, 2020, Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 18, 329, 10.6004/jnccn.2020.0011

Siefker-Radtke, 2018, Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma, J Urol, 199, 1129

Lopez-Beltran, 2004, Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis, Eur Urol, 45, 257, 10.1016/j.eururo.2003.09.018

Thông tin
Thông tin xuất bản

Pathology

Tập 53

67-85

Thông tin tác giả